Press Releases - Regeneron Pharmaceuticals Inc.
Oct 31, 2024 · Regeneron Reports Third Quarter 2024 Financial and Operating Results. Oct 24. Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI. Oct 18. Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with ...
Regeneron to Highlight Pioneering Pipeline Progress Across ...
21 hours ago · When Regeneron's Co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985.They were the first to envision making ...
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
17 hours ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic ...
News Release - Regeneron Pharmaceuticals Inc.
Jan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Regeneron to Highlight Pioneering Pipeline Progress Across ...
21 hours ago · --Regeneron Pharmaceuticals, Inc. today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology 2024 Annual Meeting ...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Dupixent® (dupilumab) Is the First and Only Biologic to ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with ...